Comparison of pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban in healthy subjects

Trial Profile

Comparison of pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2011

At a glance

  • Drugs Apixaban; Rivaroxaban
  • Indications Acute coronary syndromes; Deep vein thrombosis; Pulmonary embolism; Stroke; Venous thromboembolism
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 02 Aug 2011 New trial record
    • 23 Jul 2011 Results reported in an abstract at 23rd Congress of the International Society on Thrombosis and Haemostasis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top